Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism

Male hypogonadism (MH) is a common endocrine disorder. However, uncertainties and variations in its diagnosis and management exist. There are several current guidelines on testosterone replacement therapy that have been driven predominantly by single disciplines. The Society for Endocrinology commissioned this new guideline to provide all care providers with a multidisciplinary approach to treating patients with MH. This guideline has been compiled using expertise from endocrine (medical and nursing), primary care, clinical biochemistry, urology and reproductive medicine practices. These guidelines also provide a patient perspective to help clinicians best manage MH.

Automated summary

Male hypogonadism is a common endocrine disorder with uncertainties and variations in its diagnosis and management. Current guidelines on testosterone replacement therapy are mainly driven by single disciplines. The Society for Endocrinology commissioned a new guideline to provide a multidisciplinary approach to treating patients with MH, compiled using expertise from various practices and including a patient perspective to assist clinicians in managing MH effectively.